Armando Santoro
Impact in
- Hepatology top 0.02%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 0.02%
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Papers in
- Oncology 389
- Cancer Immunotherapy and Biomarkers 60
- CAR-T cell therapy research 55
- Colorectal Cancer Treatments and Studies 53
-
- Lymphoma Diagnosis and Treatment 218
- Co-authors
- Gianni Bonadonna (46 shared papers)Pinuccia Valagussa (38 shared papers)Salvatore Siena (10 shared papers)Eric Van Cutsem (7 shared papers)Yves Humblet (3 shared papers)David Cunningham (8 shared papers)Chris Verslype (1 shared paper)David Khayat (1 shared paper)
- Journals
- Annals of Oncology (97 papers)Blood (60 papers)Journal of Clinical Oncology (52 papers)Bone Marrow Transplantation (31 papers)European Journal of Cancer (31 papers)
- Partner nations
- ItalyUnited StatesFrance
In The Last Decade
Armando Santoro
957 papers receiving 60.8k citations
Armando Santoro's Hit Papers
Peers
Comparison fields: 5 of 181
- Hepatology 11.8k
- Oncology 23.4k
- Pathology and Forensic Medicine 12.6k
- Pulmonary and Respiratory Medicine 16.2k
- Cancer Research 6.2k
Countries citing papers authored by Armando Santoro
This map shows the geographic impact of Armando Santoro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Armando Santoro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Armando Santoro more than expected).
Fields of papers citing papers by Armando Santoro
This network shows the impact of papers produced by Armando Santoro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Armando Santoro. The network helps show where Armando Santoro may publish in the future.
Co-authors
The 25 scholars most cited alongside Armando Santoro, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 987 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Sorafenib in Advanced Hepatocellular Carcinoma Hit paper breakdown → | 2008 | 11056 |
| 2 | Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer Hit paper breakdown → | 2004 | 4215 |
| 3 | Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer Hit paper breakdown → | 2004 | 1452 |
| 4 | Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer Hit paper breakdown → | 2014 | 1236 |
| 5 | Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib Hit paper breakdown → | 2020 | 1039 |
| 6 | Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma Hit paper breakdown → | 2006 | 1031 |
| 7 | Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial Hit paper breakdown → | 2016 | 774 |
| 8 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial Hit paper breakdown → | 2012 | 724 |
| 9 | Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer Hit paper breakdown → | 2021 | 581 |
| 10 | Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial Hit paper breakdown → | 2018 | 562 |
| 11 | Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial Hit paper breakdown → | 2018 | 554 |
| 12 | Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib Hit paper breakdown → | 2014 | 500 |
| 13 | Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study Hit paper breakdown → | 2018 | 496 |
| 14 | Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients Hit paper breakdown → | 2009 | 494 |
| 15 | SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma Hit paper breakdown → | 2014 | 492 |
| 16 | Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study Hit paper breakdown → | 2012 | 485 |
| 17 | Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study Hit paper breakdown → | 1999 | 477 |
| 18 | Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Hit paper breakdown → | 1995 | 453 |
| 19 | 2009 | 424 | |
| 20 | 2009 | 419 |
About Armando Santoro
Armando Santoro is a scholar working on Oncology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine, Genetics and Hematology, having authored 987 papers that have together received 62.8k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (218 papers), Lung Cancer Treatments and Mutations (101 papers), Chronic Lymphocytic Leukemia Research (78 papers), Sarcoma Diagnosis and Treatment (63 papers), Cancer Immunotherapy and Biomarkers (60 papers), Hepatocellular Carcinoma Treatment and Prognosis (56 papers), CAR-T cell therapy research (55 papers) and Colorectal Cancer Treatments and Studies (53 papers). The work is most often cited by research in Hepatology (11.8k citations), Oncology (23.4k citations), Pathology and Forensic Medicine (12.6k citations), Pulmonary and Respiratory Medicine (16.2k citations) and Cancer Research (6.2k citations). Armando Santoro has collaborated with scholars based in Italy, United States and France. Frequent co-authors include Gianni Bonadonna, Pinuccia Valagussa, Salvatore Siena, Eric Van Cutsem, Yves Humblet, David Cunningham, Chris Verslype, David Khayat, Matthias Mueser and Andreas Harstrick. Their work appears in journals such as Annals of Oncology, Blood, Journal of Clinical Oncology, Bone Marrow Transplantation and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.